Viking Therapeutics (VKTX) Shares Outstanding (2014 - 2026)

Viking Therapeutics has disclosed Shares Outstanding (Entity) across 13 years of filings, most recently posting $116.7 million for Q2 2026.

• In Q2 2026, Shares Outstanding (Entity) rose 3.85% year-over-year to $116.7 million; the TTM figure through Jun 2026 stood at $116.7 million (up 3.85% YoY), while the FY2025 annual figure was $114.8 million, up 2.89% from the prior year.
• Shares Outstanding (Entity) came in at $116.7 million for Q2 2026 at Viking Therapeutics, up from $115.9 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $116.7 million in Q2 2026 to a low of $76.7 million in Q2 2022.
• Average Shares Outstanding (Entity) over 5 years is $100.9 million, with a median of $110.5 million recorded in 2024.
• Year-over-year, Shares Outstanding (Entity) dropped 1.98% in 2022 and jumped 38.97% in 2024.
• Over 5 years, Shares Outstanding (Entity) stood at $78.3 million in 2022, then increased by 27.93% to $100.1 million in 2023, then grew by 11.45% to $111.6 million in 2024, then rose by 2.89% to $114.8 million in 2025, then gained by 1.62% to $116.7 million in 2026.
• Per Business Quant data, the three most recent Shares Outstanding (Entity) figures were $116.7 million in Q2 2026, $115.9 million in Q1 2026, and $114.8 million in Q4 2025.